載入...
Tadalafil therapy for sarcoidosis-associated pulmonary hypertension
Abstract. Sarcoidosis-associated pulmonary hypertension (SAPH) is estimated to occur in at least 5% or more of sarcoidosis patients, and it contributes to significant morbidity and mortality. Optimal therapy for SAPH is not well established. We performed a 24-week open-label trial of tadalafil for S...
Na minha lista:
| 發表在: | Pulm Circ |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
University of Chicago Press
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5210066/ https://ncbi.nlm.nih.gov/pubmed/28090299 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/688775 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|